**Core Concept:**
XDR TB (Extensively Drug-Resistant Tuberculosis) is a form of tuberculosis (TB) that is resistant to at least rifampicin and isoniazid, which are the most potent first-line anti-TB drugs. Mycobacterium tuberculosis, the causative agent of TB, develops resistance when exposed to sub-inhibitory concentrations of antibiotics, leading to the emergence of strains that are resistant to multiple drugs.

**Why the Correct Answer is Right:**
The correct answer, D, is "isoniazid" because isoniazid is a first-line anti-TB drug that belongs to the group of drugs known as isoniazid derivatives. When Mycobacterium tuberculosis is exposed to isoniazid, it develops resistance due to mutations in the target enzyme (InhA) or the drug transporter protein (EthA). These mutations lead to reduced susceptibility or complete resistance to isoniazid.

**Why Each Wrong Option is Incorrect:**
A. Rifampicin (Rifampin): This is another first-line anti-TB drug that belongs to the rifamycin group. Resistance to rifampicin develops due to mutations in the RNA polymerase enzyme, which is the target of rifampicin. This option is incorrect because it does not involve the specific mechanisms of resistance to isoniazid.

B. Second-line drugs: This option is incorrect because XDR TB refers to drug resistance among M. tuberculosis strains that are resistant to at least isoniazid and rifampicin, which are part of the first-line drugs. Second-line drugs are used in the management of extensively drug-resistant TB (XDR TB), not extensively drug-resistant TB (XDR TB).

C. Ethionamide: Ethionamide is a second-line anti-TB drug from the group of thioamide derivatives. Resistance to ethionamide develops due to mutations in the mycobacterial target (dihydrofolate reductase) or drug transporter proteins (e.g., EthA). This option is incorrect because it relates to second-line drugs, not the first-line drugs like isoniazid and rifampicin.

**Clinical Pearl:**
Clinical pearls from this question include the importance of understanding the mechanisms of drug resistance in M. tuberculosis strains and the distinction between first-line and second-line drugs in the management of drug-resistant TB. In addition, it highlights the role of mutations in the target enzymes or drug transporter proteins in the development of drug resistance.

**Explanation:**

The correct answer is D (isoniazid) because it is a first-line drug that develops resistance through mutations in its target enzyme (InhA) and drug transporter proteins (EthA). In contrast, XDR TB requires second-line drugs like ethionamide or capreomycin, which develop resistance through different mechanisms.